The Online Investor
Daily M&A
Retiree Portfolio
Stock Option Ideas
Preferred Stock List
ChartZero.com
ChartZero

Slideshow Mergers & Acquisitions

By The Online Investor Staff, updated Mon., Feb. 8, 2:57 AM

Slide #2. POZEN Inc. Tribute Pharmaceuticals Canada Inc.

Acquirer: POZEN Inc. (POZN)
Acquiree: Tribute Pharmaceuticals Canada Inc. (TRX.CA)
Details: Aralez Pharmaceuticals Inc. ("Aralez") today announced the completion of the business combination of POZEN Inc. ("POZEN") and Tribute Pharmaceuticals Canada Inc. ("Tribute") following approval of the transaction by stockholders of POZEN and shareholders of Tribute. The combined company will operate under Aralez Pharmaceuticals Inc. ("Aralez"), a global specialty pharmaceutical company with operations in Canada, Ireland and the United States. Under the terms of the Agreement and Plan of Merger and Arrangement, each share of POZEN common stock has been converted into the right to receive one Aralez common share and each common share of Tribute (other than dissenting shares) has been exchanged for 0.1455 Aralez common shares.

Pozen is a pharmaceutical company. Co. has developed VIMOVO® with AstraZeneca AB. VIMOVO has been approved by the FDA for relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, and to decrease the risk of developing gastric ulcers in patients at risk of developing non-steroidal anti-inflammatory drug-associated gastric ulcers. Co.'s PA product candidates contain a combination of a proton pump inhibitor and enteric coated aspirin in a single tablet. Co.'s product candidates include PA32540 for the secondary prevention of cardiovascular and cerebrovascular disease in patients at risk for gastric ulcers, and PA8140, a low dose version of PA32540.

POZN SEC Filing Email Alerts Service


Open the POZN Page at The Online Investor »

Pozen is a pharmaceutical company. Co. has developed VIMOVO® with AstraZeneca AB. VIMOVO has been approved by the FDA for relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, and to decrease the risk of developing gastric ulcers in patients at risk of developing non-steroidal anti-inflammatory drug-associated gastric ulcers. Co.'s PA product candidates contain a combination of a proton pump inhibitor and enteric coated aspirin in a single tablet. Co.'s product candidates include PA32540 for the secondary prevention of cardiovascular and cerebrovascular disease in patients at risk for gastric ulcers, and PA8140, a low dose version of PA32540.

POZN SEC Filing Email Alerts Service


Open the TRX.CA Page at The Online Investor »

Company Name:  Pozen Inc.
Website:  www.pozen.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding POZN:  13
Total Market Value Held by ETFs:  $4.86M
Total Market Capitalization:  $215.00M
% of Market Cap. Held by ETFs:  2.26%
Company Name:  Tribute Pharmaceuticals Canada Inc
Website:  www.tributepharma.com
Sector:  Drugs & Pharmaceuticals
 

February 8, 2016    2:57 AM Eastern
Quotes delayed 20 minutes


Mergers & Acquisitions | www.TheOnlineInvestor.com | Copyright © 1998 - 2016, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.